Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs compared
Compare all 3 Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs side by side, used for conditions such as aids-related opportunistic infections, cytomegalovirus retinitis. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.
Full ranking · 3 drugs
- 170/100
valganciclovir hydrochloride
Valganciclovir Hydrochloride
- 2New
valcyte
Valganciclovir Hydrochloride
- 3New
zirgan
Ganciclovir
Frequently asked questions
What is the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drug class?
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 3 Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor products, each independently rated.
Are all Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs the same?
No. Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.
What conditions do Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs treat?
Per NIH RxClass drug-classification data, Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor drugs are used for conditions including aids-related opportunistic infections, cytomegalovirus retinitis.
Sources: the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.